TY  - JOUR
ID  - discovery1523150
N2  - Cyclosporine A, an inhibitor of calcineurin, exerts an immunomodulator action interfering with T cell activation. Even though novel therapeutic tools have emerged, CyA still represents a suitable option in several clinical rheumatology settings. This is the case of refractory nephritis and cytopenias associated with systemic lupus erythematosus. Furthermore, CyA is a valued therapeutic tool in the management of uveitis and thrombophlebitis in course of Behçet's disease. Topical CyA has been proven to be beneficial in the dry eye of Sjogren's syndrome, whereas oral treatment with CyA can be considered for the severe complications of adult onset Still's disease. CyA provides a therapeutic option in psoriatic arthritis, being rather effective in skin disease. CyA is currently regarded as a second-line option for patients with inflammatory myopathies refractory to standard regimen. CyA is used even in paediatric rheumatology, in particular in the management of juvenile dermatomyositis and macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Importantly, CyA has been shown to suppress the replication of HCV, and it can thus be safely prescribed to those patients with chronic hepatitis C. Noteworthy, CyA can be administered throughout the gestation course. Surely, caution should be paid to CyA safety profile, in particular to its nephrotoxicity. Even though most evidence comes from small and uncontrolled studies with few randomised controlled trials, CyA should be still regarded as a valid therapeutic tool in 2016 rheumatology.
KW  - Arthritides
KW  -  Connective tissue diseases
KW  -  Cyclosporine
KW  -  Hepatitis C virus
KW  -  Rheumatology
KW  -  Vasculitides
EP  - 423
AV  - public
Y1  - 2017/06//
TI  - The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review
SN  - 1559-0267
UR  - http://dx.doi.org/10.1007/s12016-016-8582-3
A1  - Chighizola, CB
A1  - Ong, VH
A1  - Meroni, PL
JF  - Clinical Reviews in Allergy & Immunology
SP  - 401
VL  - 52
N1  - This version is the author accepted manuscript. For information on re-use, please refer to the publisher?s terms and conditions.
IS  - 3
ER  -